Tin tức & Cập nhật

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

Individuals with high adherence to the Mediterranean diet (MD) appear to benefit from a reduced risk of rheumatoid arthritis (RA), suggests a study.